Here are Siltanen’s preview comments as Aiforia reports its H2 results on Friday, March 6. 
We expect Aiforia’s revenue growth to have accelerated towards the end of the year, supported by the ramp-up of clinical customer accounts. We estimate the result to have remained loss-making. In the report, our focus will be particularly on revenue growth, the development of the order book, and the updated assessment of the adequacy of the financial position.